Alocrest vinorelbine tartrate: Additional Phase I data

Additional data from the North American, Phase I HBS501 trial showed that the MTD of Alocrest in heavily pre-treated patients was 28 mg/m 2 given on days 1 and 8 every 21 days. The MTD was not reached...